A real-world intention-to-treat analysis of a decade’s experience of treatment of hepatitis C with interferon-based therapies

Name	World Continuing Education Alliance
Activity Title	A real-world intention-to-treat analysis of a decade’s experience of treatment of hepatitis C with interferon-based therapies
Details	Data from the World Health Organization suggest that 130–150 million people are infected with chronic hepatitis C worldwide, a significant proportion of whom will develop liver cirrhosis or cancer. There are seven known genotypes of HCV, although it is possible for patients to be infected with more than one genotype concurrently. Until 2011, the only approved treatment option for patients infected with HCV was a pegylated interferon (PegIFN) plus ribavirin (RBV)-based regimen administered for 48 weeks for genotype 1, and 24 weeks for genotypes 2 and 3. Sustained virological response (SVR) rates reported in the registration studies for the dual therapy, PegIFN plus RBV, were 42–52% for genotype 1 and 76–88% for genotypes 2 and 3. In 2011, two first-generation protease inhibitors, telaprevir and boceprevir, were licensed for use alongside PegIFN plus RBV for patients with HCV genotype 1. This triple therapy improved SVR rates for genotype 1 patients from 42–52% to 66–75%. Although patien...
Competence	Public Health
Start Date	<span class="not-set">(not set)</span>
End Date	<span class="not-set">(not set)</span>
Event Time	11:15 AM
Location	World Continuing Education Alliance eLearning System
Cost (UGX)	0
CPD Points	1